on Medacta Group SA (isin : CH0468525222)
Medacta Group Announces Record 2025 Results and Positive Outlook
Medacta Group SA reported a significant financial year in 2025 with revenues reaching €683.8 million, reflecting an 18.5% increase in constant currency. This growth is attributed to the company's strategic innovations and global market expansions. Adjusted EBITDA rose 19.1% to €190.8 million, while net profit increased by 31% to €95.5 million.
The company also announced a proposed dividend increase of 59.4% to CHF 1.10 per share. The acquisition of Parcus Medical, a sports medicine specialist, contributed positively to the revenue. Medacta's geographic market expansion saw robust growth, particularly in Asia Pacific and North America.
Looking ahead, Medacta targets a 10-14% revenue increase in 2026. The company remains committed to sustainable innovation and enhancing its supply chain and production capabilities to meet future demands.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Medacta Group SA news